ScoreWhy is Rani Therapeutics Holdings, Inc. ?
1
Poor Management Efficiency with a low ROE of 0%
- The company has reported losses. Due to this company has reported negative ROE
2
With a growth in Net Sales of 16.91%, the company declared Very Positive results in Mar 26
- The company has declared positive results for the last 7 consecutive quarters
- OPERATING CASH FLOW(Y) Highest at USD -17.07 MM
- NET SALES(HY) Higher at USD 3.17 MM
- NET PROFIT(HY) Higher at USD -16.76 MM
3
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 54.02%, its profits have risen by 23.6%
4
Reducing Promoter Confidence
- Promoters have decreased their stake in the company by -3.04% over the previous quarter and currently hold 15.36% of the company
- Promoters decreasing their stake may signify reduced confidence in the future of the business
5
Market Beating Performance
- The stock has generated a return of 54.02% in the last 1 year, much higher than market (S&P 500) returns of 25.41%
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Rani Therapeutics Holdings, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Rani Therapeutics Holdings, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Rani Therapeutics Holdings, Inc.
54.02%
-0.29
282.94%
S&P 500
25.41%
1.92
13.25%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
18.94%
EBIT Growth (5y)
-184.80%
EBIT to Interest (avg)
-25.70
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.93
Sales to Capital Employed (avg)
0.08
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
52.91%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
3.04
EV to EBIT
-1.36
EV to EBITDA
-1.39
EV to Capital Employed
-3.39
EV to Sales
31.81
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-122.31%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
No Trend
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend19What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD -17.07 MM
NET SALES(HY)
Higher at USD 3.17 MM
NET PROFIT(HY)
Higher at USD -16.76 MM
RAW MATERIAL COST(Y)
Fallen by -290.86% (YoY
EPS(Q)
Highest at USD -0.04
-4What is not working for the Company
NET PROFIT(HY)
At USD -16.76 MM has Grown at -34.14%
Here's what is working for Rani Therapeutics Holdings, Inc.
Net Sales
At USD 3.17 MM has Grown at 164.08%
Year on Year (YoY)MOJO Watch
Sales trend is very positive
Net Sales (USD MM)
Operating Cash Flow
Highest at USD -17.07 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Net Sales
Higher at USD 3.17 MM
than preceding 12 month period ended Mar 2026MOJO Watch
In the half year the company has already crossed sales of the previous twelve months
Net Sales (USD MM)
Net Profit
Higher at USD -16.76 MM
than preceding 12 month period ended Mar 2026MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (USD MM)
EPS
Highest at USD -0.04
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (USD)
Raw Material Cost
Fallen by -290.86% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Rani Therapeutics Holdings, Inc.
Net Profit
At USD -16.76 MM has Grown at -34.14%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is negative
Net Profit (USD MM)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
